Dr. Antonin “Tony” De Fougerolles
Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies) and in helping build several multi-billion dollar companies from start-up stage. Prior to joining Evox, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations and played a key role in the approval of the 1st single domain antibody drug, caplacizumab. Prior to Ablynx, Tony was founding CSO at Moderna pioneering modified mRNA as a new therapeutic and vaccine modality and is an inventor of the mRNA chemistry and LNP delivery technology that forms the basis of both approved covid-19 mRNA vaccines, CSO of antibody-based immuno-oncology company Tolerx Inc, and VP Research at Alnylam where he helped develop RNAi as a new therapeutic modality including overseeing the development of the1st approved RNAi delivery system and several approved RNAi drugs including inclisiran. Also, Tony has been Principal Investigator on over $80m in grants, has over 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He also serves on the Board of Walking Fish Therapeutics and is an advisor to MiNA Therapeutics and LIfT BioSciences. Tony earned his Ph.D. in Immunology from Harvard University.
Dr. Per Lundin
Dr. Per Lundin is Co-Founder & Chief Business Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and ultimately sold the business in a PE-led trade sale. Dr Lundin serves as non-executive director of AAV gene therapy company Combigene (Nasdaq First North: COMBI) and board director of Juvenile Diabetes Research Foundation UK (JDRF UK). He is a qualified European Patent Attorney with extensive business development and licensing experience; he earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.
Dr. Sonya Montgomery
Sonya’s extensive experience in early development includes a focus on translational medicine, leading programmes in gene therapy, biologics, including antisense RNA, and small molecules. She has led successful interactions with health authorities globally, supporting IND/CTA, first-in-class NMEs, and negotiation of a SPA leading to NDA and MAA. Prior to joining Evox, Sonya was most recently at Gyroscope Therapeutics, where she established and led clinical development, translational medicine and clinical genetics. Previously, Sonya has held leadership positions in clinical development as VP Clinical Development at ProQR leading the company’s cystic fibrosis business. In 2012, she held the position of Executive Director Clinical Development, at Relypsa, following a position at Pfizer as Clinical Lead, directing programmes in nephrology, diabetes, metabolism, and cardiovascular disease. She joined industry in 1997, and early in her career combined biopharmaceutical research with a clinical practice.
Kerry is a strategic and commercially-focused leader with significant experience in business change and transformation. Motivated by a passion to drive the culture and ethos of a company, as Head of HR at Centrica Customer Services she enabled the organisation to effectively engage with both their employees and with key audiences. With the ability to influence and build strong relationships at all levels across organisations, oversee and project manage large-scale restructuring and organisational change, Kerry is motivated to deliver through values, employee engagement and communication.
Peter has more than 30 years of process development experience in the biopharmaceutical industry, including cell and gene therapies. During those years, he was involved in bringing more than 16 products to commercialization. Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics, where he led late-stage CMC activities for the AUTO1 (obe-cel) CD19 CAR T cell therapy program. Prior to that, Mr. Jones held several positions of increasing responsibility at Oxford Biomedica, including Senior Director, Head of Operational Strategy, Head of Technical Operations, and Head of Manufacturing Development supporting CMC-related activities for the Novartis’ CAR T cell therapy, Kymriah® and Orchard Therapeutics’ ADA-SCID gene therapy programs. Peter also served 20 years in multiple leadership roles spanning Discovery to Manufacturing at GlaxoSmithkline and Genzyme. Peter has a BSc in Applied Biology from the University of Hertfordshire and a MSc (Eng) in Biochemical Engineering from University College, London. He is also a chartered chemical engineer, Fellow of the Institution of Chemical Engineers and a Royal Academy of Engineering Visiting Professor in manufacturing of advanced therapies at Aston University.
Dr. David Lowe
David’s extensive experience at Astra Zeneca includes having accountability for the isolation and optimisation of antibodies, proteins, and peptides for therapeutic development. He and his team delivered lead molecules for the Respiratory, Inflammatory, and Autoimmunity antibody projects. David was the Global Head of In Vivo Expressed Biologics at AZ focusing on exploring and advancing new technologies such as AAV, DNA, mRNA and exosome delivery of biologics. David spent nearly 10 years at Cambridge Antibody Technology, prior to it being acquired by Astra Zeneca, where he led antibody engineering to develop novel antibody-based drugs. David has over 40 scientific publications, and is an inventor on numerous patents. David earned his Ph.D. from the University of Cambridge.